A novel asthma burden score that incorporated asthma exacerbations and healthcare utilization better reflected disease severity and predicted asthma remission with high sensitivity and specificity, ...
Dupilumab was linked to improved lung function, asthma control, QOL, and biomarkers for up to 2 years in patients with uncontrolled severe asthma.
Most patients with severe asthma substantially reduced or even discontinued oral corticosteroid use with addition of tezepelumab (Tezspire) in the single-arm WAYFINDER trial. At both 28 and 52 weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results